 |
answer text |
<p>Porton Biopharma Ltd (PBL) are implementing a series of initiatives to increase
capacity and supply in both the short and long term. These include the following:</p><p>-
Extending operational activities to 24 hours a day, seven days a week to maximise
fermentation of the product;</p><p>- Implementing an ongoing capital programme including
construction of a new pharmaceutical fermentation facility. The facility was completed
in April 2018 and is currently undergoing testing; it has an increased capacity fermentation
suite which will enable PBL to manufacture at larger scale and is due to start producing
product Q3 2019 for regulatory approval to market;</p><p>- A new filling and freeze-drying
building was completed in February 2016. The installation of a new filling line which
covers the entire process, including vial washing, filling, stoppering and freeze
drying. The new line has been designed with systems which monitor all critical parameters
throughout the process to accelerate batch release and will accommodate increased
capacity. The beneficial use of this and the fermentation facility will coincide to
maximise increased product output; and</p><p>- Sourcing replacement suppliers, including
for new stoppers and new vials for the product, ensuring that maximum batch sizes
can be achieved with minimal product rejects. This programme is complete.</p><p> </p><p>PBL
has made significant investments into increasing product capacity and will continue
to release future batches as soon as they become available to Jazz Pharmaceuticals
(who are responsible for the packaging/distribution and allocation of worldwide product
supply).</p>
|
|
